Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/58215
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Catharina Busch | en_US |
dc.contributor.author | Dinah Zur | en_US |
dc.contributor.author | Samantha Fraser-Bell | en_US |
dc.contributor.author | Inês Laíns | en_US |
dc.contributor.author | Ana Rita Santos | en_US |
dc.contributor.author | Marco Lupidi | en_US |
dc.contributor.author | Carlo Cagini | en_US |
dc.contributor.author | Pierre Henry Gabrielle | en_US |
dc.contributor.author | Aude Couturier | en_US |
dc.contributor.author | Valérie Mané-Tauty | en_US |
dc.contributor.author | Ermete Giancipoli | en_US |
dc.contributor.author | Giuseppe D.Amico Ricci | en_US |
dc.contributor.author | Zafer Cebeci | en_US |
dc.contributor.author | Patricio J. Rodríguez-Valdés | en_US |
dc.contributor.author | Voraporn Chaikitmongkol | en_US |
dc.contributor.author | Atchara Amphornphruet | en_US |
dc.contributor.author | Isaac Hindi | en_US |
dc.contributor.author | Kushal Agrawal | en_US |
dc.contributor.author | Jay Chhablani | en_US |
dc.contributor.author | Anat Loewenstein | en_US |
dc.contributor.author | Matias Iglicki | en_US |
dc.contributor.author | Matus Rehak | en_US |
dc.date.accessioned | 2018-09-05T04:21:15Z | - |
dc.date.available | 2018-09-05T04:21:15Z | - |
dc.date.issued | 2018-08-01 | en_US |
dc.identifier.issn | 14325233 | en_US |
dc.identifier.issn | 09405429 | en_US |
dc.identifier.other | 2-s2.0-85046451948 | en_US |
dc.identifier.other | 10.1007/s00592-018-1151-x | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046451948&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/58215 | - |
dc.description.abstract | © 2018, Springer-Verlag Italia S.r.l., part of Springer Nature. Aims: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting. Methods: To be included in this retrospective multicenter, case–control study, eyes were required: (1) to present with early refractory DME, as defined by visual acuity (VA) gain ≤ 5 letters or reduction in central subfield thickness (CST) ≤ 20%, after a loading phase of anti-VEGF therapy (three monthly injections) and (2) to treat further with (a) anti-VEGF therapy or (b) DEX implant. Main outcome measures were change in visual acuity (VA) and central subfield thickness (CST) at 12 months. Due to imbalanced baseline characteristics, a matched anti-VEGF group was formed by only keeping eyes with similar baseline characteristics as those in the DEX group. Results: A total of 110 eyes from 105 patients were included (anti-VEGF group: 72 eyes, DEX group: 38 eyes). Mean change in VA at 12 months was − 0.4 ± 10.8 letters (anti-VEGF group), and + 6.1 ± 10.6 letters (DEX group) (P = 0.004). Over the same period, mean change in CST was + 18.3 ± 145.9 µm (anti-VEGF group) and − 92.8 ± 173.6 µm (DEX group) (P < 0.001). Eyes in the DEX group were more likely to gain ≥ 10 letters (OR 3.71, 95% CI 1.19–11.61, P = 0.024) at month 12. Conclusions: In a real-world setting, eyes with DME considered refractory to anti-VEGF therapy after three monthly injections which were switched to DEX implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with anti-VEGF therapy. | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Medicine | en_US |
dc.title | Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | Acta Diabetologica | en_US |
article.volume | 55 | en_US |
article.stream.affiliations | Universitatsklinikum Leipzig und Medizinische Fakultat | en_US |
article.stream.affiliations | Tel Aviv Sourasky Medical Center | en_US |
article.stream.affiliations | Tel Aviv University, Sackler Faculty of Medicine | en_US |
article.stream.affiliations | The University of Sydney | en_US |
article.stream.affiliations | Universidade de Coimbra, Faculdade de Medicina | en_US |
article.stream.affiliations | Association for Innovation and Biomedical Research on Light | en_US |
article.stream.affiliations | Harvard Medical School | en_US |
article.stream.affiliations | Instituto Politcnico do Porto | en_US |
article.stream.affiliations | Universita degli Studi di Perugia | en_US |
article.stream.affiliations | Centre Hospitalier Universitaire de Dijon | en_US |
article.stream.affiliations | Centre des Sciences du Gout et de l'Alimentation | en_US |
article.stream.affiliations | Universite Paris 7- Denis Diderot | en_US |
article.stream.affiliations | Universita degli Studi di Sassari | en_US |
article.stream.affiliations | Istanbul Tip Fakultesi | en_US |
article.stream.affiliations | Tecnologico de Monterrey | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
article.stream.affiliations | Rangsit University | en_US |
article.stream.affiliations | L.V. Prasad Eye Institute India | en_US |
article.stream.affiliations | Tel Aviv University | en_US |
article.stream.affiliations | Universidad de Buenos Aires | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.